Nasdaq: Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment ...
Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment ...
Nasdaq: Firefly Neuroscience, Inc. Advances Neuropharmacology and Psychiatry with Innovative BNA™ Platform Supported by New Clinical Studies
Firefly Neuroscience, Inc. Advances Neuropharmacology and Psychiatry with Innovative BNA™ Platform Supported by New Clinical Studies
Centessa Pharmaceuticals plc announced the appointment of Dr. Stephen Kanes as Chief Medical Officer, bringing over 30 years of experience in neuroscience and clinical psychiatry. Dr. Kanes, who ...
Business Wire: Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major ...
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major ...
FierceBiotech: Alto Neuroscience preps IPO to push precision psychiatry therapies through the clinic
Alto Neuroscience preps IPO to push precision psychiatry therapies through the clinic
Business Wire: Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor
Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor
Business Wire: Emerging Clinical-Stage Neuroscience Company Nuvie Bio Announces Positive Phase 1 Data with its Lead Migraine Program
Emerging Clinical-Stage Neuroscience Company Nuvie Bio Announces Positive Phase 1 Data with its Lead Migraine Program
Mental health is in crisis worldwide. While the neurosciences are advancing rapidly, psychiatry still struggles to diagnose and effectively treat many disorders. The Synapsy Center for Neuroscience ...